Novel mechanistic insights into ectodomain shedding of egfr ligands amphiregulin and TGF-α: Impact on gastrointestinal cancers driven by secondary bile acids

Cancer Research

Volumn 74, Issue 7, 2014, Pages 2062-2072

  Nagathihalli, Nagaraj S ^a   Beesetty, Yugandhar ^a   Lee, Wooin ^b   Washington, M Kay ^a   Chen, Xi ^a   Lockhart, A Craig ^c   Merchant, Nipun B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BILE ACID; CYCLIN D1; DEOXYCHOLIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL SURFACE; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ADAM PROTEINS; BILE ACIDS AND SALTS; CYCLIN D1; DEOXYCHOLIC ACID; GASTROINTESTINAL NEOPLASMS; GLYCOPROTEINS; HCT116 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PANCREAS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84897443202     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2329     Document Type: Article

References (50)

1. Bayerdorffer E, Mannes GA, Richter WO, Ochsenkuhn T, Wiebecke B, Kopcke W, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993;104:145-51.
2. Debruyne PR, Bruyneel EA, Li X, Zimber A, Gespach C, Mareel MM. The role of bile acids in carcinogenesis. Mutat Res 2001;480-481: 359-69.
3. Bernstein H, Bernstein C, Payne CM, Dvorak K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol 2009;15:3329-40.
4. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffiths AP, Baxter JN, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NFkappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25:317-23.
5. Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003;52:174-80.
6. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499:97-101.
7. Bernstein C, Bernstein H, Payne CM, Dvorak K, Garewal H. Field defects in progression to gastrointestinal tract cancers. Cancer Lett 2008;260:1-10.
8. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557-60.
9. Carpenter G. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J Cell Biol 1999;146:697-702.
10. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998;102:1385-92.
11. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003;278:9435-40.
12. Merchant NB, Rogers CM, Trivedi B, Morrow J, Coffey RJ. Liganddependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery 2005;138:415-21.
13. Merchant NB, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ, Graves-Deal R, et al. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008;14:1182-91.
14. Lee DC, Sunnarborg SW, Hinkle CL, Myers TJ, Stevenson MY, Russell WE, et al. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann N Y Acad Sci 2003;995:22-38.
15. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 2007;117:337-45.
16. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003;284:2-13.
17. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003;22:2411-21.
18. Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, et al. Phosphorylation of TNF-Alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 2006;103:6901-6.
19. Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/ cateninmediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res 2002;62:2669-74.
20. Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 2010;9:2322-32.
21. Allgayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma -An indicator of poor clinical prognosis. Cancer 2002;94:344-51.
22. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, EvansCP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-75.
23. Serrels B, Serrels A, Mason SM, Baldeschi C, Ashton GH, Canel M, et al. A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. Carcinogenesis 2009;30:249-57.
24. Maretzky T, Zhou W, Huang XY, Blobel CP. A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17. Oncogene 2011;30: 611-8.
25. Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, et al. Src and ADAM-17-mediated shedding of transforming growth factor-Alpha is a mechanism of acute resistance to TRAIL. Cancer Res 2008;68:8312-21.
26. Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas 2009;38:e1-6.
27. Scheiman JM, Meise KS, Greenson JK, Coffey RJ. Transforming growth factor-Alpha (TGF-Alpha) levels in human proximal gastrointestinal epithelium. Effect of mucosal injury and acid inhibition. Dig Dis Sci 1997;42:333-41.
28. Nagaraj NS, Beckers S, Mensah JK, Waigel S, Vigneswaran N, Zacharias W. Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett 2006;165: 182-94.
29. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
30. Nagaraj NS, Vigneswaran N, Zacharias W. Hypoxia inhibits TRAILinduced tumor cell apoptosis: involvement of lysosomal cathepsins. Apoptosis 2007;12:125-39.
31. Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 2011;17:483-93.
32. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol 2011;54:1263-72.
33. Hong J, Behar J, Wands J, Resnick M, Wang LJ, DeLellis RA, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010;59:170-80.
34. Santiskulvong C, Sinnett-Smith J, Rozengurt E. EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin. Am J Physiol Cell Physiol 2001;281: C886-98.
35. Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogenactivated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis 2001;22:35-41.
36. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985-93.
37. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
38. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, et al. Increases of amphiregulin and transforming growth factor-Alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65: 9176-84.
39. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005;6:32-43.
40. Castillo J, Erroba E, Perugorria MJ, Santamaria M, Lee DC, Prieto J, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006;66:6129-38.
41. Cook PW, Pittelkow MR, Keeble WW, Graves-Deal R, Coffey RJ Jr, Shipley GD. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 1992;52: 3224-7.
42. Saeki T, Stromberg K, Qi CF, Gullick WJ, Tahara E, Normanno N, et al. Differential immunohistochemical detection ofamphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res 1992; 52:3467-73.
43. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15.
44. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005;6:322-7.
45. Dhillon AS, Hagan S, Rath O, Kolch W.MAPkinase signalling pathways in cancer. Oncogene 2007;26:3279-90.
46. Morgillo F, Lee HY. Resistance to epidermal growth factor receptortargeted therapy. Drug Resist Updat 2005;8:298-310.
47. Chong CR, Janne PA. The quest to overcome resistance to EGFRtargeted therapies in cancer. Nat Med 2013;19:1389-400.
48. Busser B, Sancey L, Josserand V, Niang C, Favrot MC, Coll JL, et al. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small cell lung cancers. Mol Ther 2010;18:528-35.
49. Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004;41:1008-16.
50. Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-Type metastatic colorectal cancer. Br J Cancer 2011;104:488-95.